The invention relates to a pharmaceutical dosage form exhibiting a breaking strength of at least 500 N, said dosage form containing- a pharmacologically active ingredient(A)；- a physiologically acceptable polymer(B) obtainable by polymerization of a monomer composition comprising an ethylenically unsaturated monomer bearing an anionic functional group, in protonated form or a physiologically acceptable salt thereof；- a polyalkylene oxide(C) having a weight average molecular weight of at least 200,000 g/mol,wherein the content of the polyalkylene oxide(C) is at least 20 wt%, based on the total weight of the dosage form； wherein the pharmacologically active ingredient(A) is present in a controlled-release matrix comprising the polymer(B) and the polyalkylene oxide(C).本發明係關於一種展現至少500 N斷裂強度之醫藥劑型，所述該劑型含有-一藥理活性成分(A)；-藉由聚合含有負載一質子化型陰離子官能基之乙烯化不飽和單體之單體組成物所獲得之一生理上可接受聚合物(B)或其生理上可接受鹽；以及-具有重均分子量至少200,000 g/mol之一聚氧亞烷(C)，其中該聚氧亞烷(C)之含量為根據該劑型總重之至少20 wt%；其中該藥理活性成分(A)係存在於包含該聚合物(B)和該聚氧亞烷(C)之一控釋基質內。
